GlassScriptPhysician profile
Marissa Citarelli
NPI 1578188363
$3,643.72
in general payments reported to CMS, 2019-2025
44 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $139 · 2023: $24.69 · 2024: $1,320 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,429.34 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $394.74 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $350.30 | 2024-2025 | Tagrisso, Lynparza, Enhertu |
| Pfizer INC. | $314.80 | 2024-2025 | |
| Sobi, INC | $197.75 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $187.72 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $181.13 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $137.20 | 2024-2025 | Rybrevant, Darzalex, Carvykti |
| Genentech USA, INC. | $132.38 | 2024-2025 | Tecentriq, Polivy, Itovebi |
| Ipsen Biopharmaceuticals, INC | $128.60 | 2024-2025 | Onivyde |
| Abbvie INC. | $121.78 | 2024-2025 | |
| Astellas Pharma US INC | $120.38 | 2024-2025 | Padcev, Xtandi, Xospata |
| Genzyme Corporation | $113.88 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $109.53 | 2024-2025 | Libtayo, Lynozyfic |
| Takeda Pharmaceuticals U.S.A., INC. | $101.28 | 2024-2025 | Iclusig, Vpriv, Ninlaro |
| Legend Biotech USA INC. | $91.01 | 2024-2025 | Carvykti |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $79.61 | 2024-2025 | |
| Daiichi Sankyo INC. | $78.86 | 2023-2025 | Enhertu, Injectafer |
| Exelixis INC. | $74.99 | 2024 | |
| Pharmacosmos Therapeutics INC. | $62.25 | 2024-2025 | Monoferric |
| Azurity Pharmaceuticals, INC. | $48.28 | 2025 | Danziten, Vivimusta |
| Emd Serono, INC. | $45.58 | 2024-2025 | |
| Lilly USA, LLC | $44.99 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Caris Mpi, INC. | $43.83 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $42.78 | 2025 | |
| Karyopharm Therapeutics INC. | $38.10 | 2024-2025 | Xpovio |
| Coherus Oncology, INC. | $37.31 | 2024 | |
| Array Biopharma INC | $32.30 | 2024-2025 | Braftovi, Lorbrena, Tukysa |
| Gilead Sciences, INC. | $29.96 | 2025 | Trodelvy |
| Kyowa Kirin, INC. | $24.06 | 2024 | Poteligeo |
| Stemline Therapeutics INC. | $23.84 | 2025 | Orserdu |
| Iovance Biotherapeutics, INC. | $23.83 | 2025 | Amtagvi |
| Beone Medicines USA, INC. | $23.73 | 2025 | Brukinsa |
| Spectrum Pharmaceuticals INC. | $21.57 | 2024 | Rolvedon |
| Glaxosmithkline, LLC. | $21.33 | 2025 | Jemperli, Zejula |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.78 | 2025 | |
| Tersera Therapeutics LLC | $18.29 | 2025 | Xermelo |
| Adc Therapeutics America, INC. | $17.70 | 2025 | |
| Acrotech Biopharma INC. | $17.65 | 2025 | Beleodaq |
| Progenics Pharmaceuticals, INC. | $16.85 | 2024 | |
| Genmab U.S., INC. | $16.33 | 2025 | Epkinly |
| Celgene Corporation | $16.21 | 2024 | Pomalyst |
| Puma Biotechnology, INC. | $15.56 | 2025 | |
| Apellis Pharmaceuticals, INC. | $14.93 | 2025 | Empaveli |
| Rigel Pharmaceuticals, INC. | $11.74 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Citarelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.